An energy utilization system and a method for manufacturing a carbon-containing material are provided that make it possible to obtain a carbon-containing material while suppressing release of carbon dioxide and reducing carbon dioxide. An energy utilization system (1) comprises: a heat utilization cycle (30) that has a high-temperature-utilizing heat exchange unit (36) for adjusting the temperature of a heat medium by utilizing energy obtained from renewable energy or waste heat, the heat utilization cycle (30) having a heat medium circulating therein; and an electrolytic reduction device (70) for electrolytically reducing an electrolytic solution in which carbon dioxide is dissolved. The electrolytic reduction device (70) electrolytically reduces the electrolytic solution of which the temperature has been adjusted by being in thermal contact with the heat medium. The electrolytic reduction device (70) includes: a cylindrical electrolytic cell casing (79) extending in a first direction; an anode (71) provided inside the electrolytic cell casing (79) and extending in the first direction; a cylindrical cathode (72) which is positioned inside the electrolytic cell casing (79) and outside the anode (71) when viewed in the first direction, and which extends in the first direction; and an electrolytic solution flow path (73) for allowing the electrolytic solution to flow in the first direction between the anode (71) and the cathode (72).
C25B 9/00 - Cellules ou assemblages de cellulesÉléments de structure des cellulesAssemblages d'éléments de structure, p. ex. assemblages d'électrode-diaphragmeCaractéristiques des cellules relatives aux procédés
Provided are a detoxifying agent and detoxifying agent kit for simultaneous detoxification of CO and HCN in the body. The detoxifying agent for removal of carbon monoxide and hydrogen cyanide in the body includes as active ingredients a first inclusion complex wherein a first cyclodextrin dimer represented by general formula (1) below clathrates a first water-soluble metal porphyrin in which the central metal is divalent, and a second inclusion complex wherein a second cyclodextrin dimer represented by general formula (2) below clathrates the first water-soluble metal porphyrin in which the central metal is divalent, and further includes a reducing agent if necessary.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A method for producing a metal carbide, the method including: an electrode production step in which a first molten salt containing carbonate ions and at least one kind of first metal ions selected from the group consisting of alkali metal ions and alkaline earth metal ions is prepared, and a second electrode is obtained by applying a voltage to the first molten salt so as to have a precipitate containing carbon precipitated on a first electrode; and an electrolysis step in which a voltage is applied to a second molten salt containing at least one kind of second metal ions selected from the group consisting of alkali metal ions and alkaline earth metal ions using the second electrode so as to obtain a carbide composition that contains a carbide of the second metal.
C07C 1/32 - Préparation d'hydrocarbures à partir d'un ou plusieurs composés, aucun d'eux n'étant un hydrocarbure à partir de composés renfermant des hétéro-atomes autres que l'oxygène ou les halogènes, ou en addition à ceux-ci
This method for producing metal carbide comprises: preparing a molten salt containing at least one type of first metal ions selected from the group consisting of alkali metal ions and alkaline earth metal ions; readying an electrode containing carbon; and applying a voltage to the molten salt using the electrode to obtain a metal carbide composition containing carbide of the first metal.
C07C 1/32 - Préparation d'hydrocarbures à partir d'un ou plusieurs composés, aucun d'eux n'étant un hydrocarbure à partir de composés renfermant des hétéro-atomes autres que l'oxygène ou les halogènes, ou en addition à ceux-ci
A method for producing a hydrocarbon, including: preparing a molten salt containing an oxide of a first metal; adding carbon dioxide to the molten salt; obtaining precipitates containing a first metal carbide by applying a voltage to the molten salt containing carbon dioxide; and obtaining a gas containing a hydrocarbon and a hydroxide of the first metal by hydrolyzing the first metal carbide.
C07C 1/12 - Préparation d'hydrocarbures à partir d'un ou plusieurs composés, aucun d'eux n'étant un hydrocarbure à partir d'oxydes de carbone à partir d'anhydride carbonique avec de l'hydrogène
C01B 32/935 - Carbures de métaux alcalins, de strontium, de baryum ou de magnésium
A method for producing a hydrocarbon including: preparing a molten salt containing a carbonate of a first metal; obtaining precipitates containing a first metal carbide by applying a voltage to the molten salt; and obtaining a gas containing the hydrocarbon and a hydroxide of the first metal by hydrolyzing the first metal carbide.
An energy utilization system includes a circulation circuit. The circulation circuit includes a pump, a heating section, an electrolytic reduction apparatus, and a thermal energy recovery section. The pump receives a heating medium and outputs the heating medium. The heating section heats the heating medium by using renewable energy or energy obtained from waste heat. The electrolytic reduction apparatus heats an electrolytic solution with heat from the heating medium. The circulation circuit circulates the heating medium. A method for producing a carbon-containing material includes heating a heating medium circulating in a circulation circuit by using renewable energy or energy obtained from waste heat, and performing electrolytic reduction by heating an electrolytic solution with heat from the heating medium that has been heated.
Realized are a carbon support for a fuel cell catalyst and a catalyst for a fuel cell which have excellent durability and excellent catalytic activity when a catalyst metal is supported. A carbon support according to an embodiment of the present invention has diffraction peaks of a (002) plane which are observed at least at 2θ=22.5° to 25°, 26°, and 26.5° in an X-ray diffraction spectrum with CuKα rays, has an intensity ratio I(P1)/I(P2) between a peak P1 at 2θ=26° and a peak P2 at 2θ=26.5° of not less than 1.4, and has a BET specific surface area of not less than 1000 m2/g.
An ultrasonic light deflector 1 provided with an ultrasound emission unit 2 for emitting ultrasound and a transparent material part 3 through which ultrasound propagates and through which light is transmitted, the ultrasonic light deflector 1 characterized in that the ultrasound emission unit 2 emits ultrasound towards a light beam L in the transparent material part 3 so that the direction of travel of the ultrasound and the direction of travel of the light beam L in the transparent material part 3 intersect, and the transparent material part 3 produces a static refractive index change and causes the light beam L to deflect while the ultrasound is being emitted.
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
An SPR ultrasonic sensor 110 comprises a prism 111 that allows a laser beam to pass therethrough and a metallic membrane 112 that reflects a laser beam. In the ultrasonic sensor, surface plasmon resonance is generated when a laser beam is incident on the metallic membrane 112, and the resonance angle is shifted when the metallic membrane 112 is irradiated with an ultrasonic wave. The ultrasonic sensor is characterized in that the metallic membrane 112 is formed only on a portion of a first surface 111A such that the area of a laser-beam irradiation spot formed on said surface 111A includes a metallic area and a non-metallic area.
The present invention provides a method for manufacturing diamond, comprising electrolytically reducing carbon dioxide into diamond to obtain diamond in an electrolytic reduction apparatus having an anode, a cathode, and an electrolytic solution containing carbon dioxide, wherein the electrolytic solution comprises an ionic liquid.
Provided is a novel compound having self-assembly activity. The compound is a compound represented by chemical formula (1), a tautomer or stereoisomer thereof, or a salt of these. In chemical formula (I), R122-R11, R11is a hydrogen atom or a discretionary substituent, R2and R3are each a hydrogen atom, a halogen, a nitro group, a straight-chain or branched alkyl group, a straight-chain or branched alkoxy group, or a cyano group, one or more hydrogen atoms of the alkyl group or the alkoxy group may additionally be substituted or not substituted with a substituent, or R2and R3 may be integrated and form a cyclic structure together with the benzene ring to which these moieties are bonded, each instance of X is a hydrogen atom or a discretionary substituent, the individual instances of X may be the same or different, and Z is a hydrogen atom or a discretionary substituent.
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/635 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p. ex. sulfanilamide, p-nitrobenzènesulfonohydrazide contenant un hétérocycle, p. ex. sulfadiazine
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07D 495/22 - Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle dans lesquels le système condensé contient au moins quatre hétérocycles
14.
GOLD-SUPPORTED CARBON CATALYST AND METHOD FOR MANUFACTURING SAME
A gold-supported carbon catalyst includes gold fine particles supported on carbon black, wherein the gold fine particles are coordinated by an alkanethiol at a coverage of from 10% to 70%, and wherein the gold fine particles have an average particle diameter of from 1.0 nm to 1.5 nm.
An electrode used for oxygen reactions, the electrode being excellent in catalytic activity and stability, a method of producing the electrode, and an electrochemical device using the electrode are provided. This electrode includes, as an oxygen catalyst, an oxide that has peaks at positions of 2θ=34.88°±1.00°, 50.20°±1.00°, and 59.65°±1.00° in an X-ray diffraction measurement using a CuKα ray and has constituent elements of bismuth, ruthenium, sodium, and oxygen.
[Problem] One purpose of the present invention is to provide a vapor generation material which enables the achievement of a vapor of a vaporizable substance stably with high efficiency, while suppressing outgas and splash. Another purpose of the present invention is to provide a vapor generation material which enables a vaporizable substance to be vaporized at low temperatures. Another purpose of the present invention is to provide a vapor generation material which is in a solid state and has improved transportability and handleability. [Solution] In order to achieve the above, a vapor generation material according to the present invention generates a vapor by mean of heating, and is characterized by comprising at least one material that is a vaporizable substance, and a supporting material.
C23C 16/448 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c.-à-d. procédés de dépôt chimique en phase vapeur [CVD] caractérisé par le procédé de revêtement caractérisé par le procédé utilisé pour produire des courants de gaz réactifs, p. ex. par évaporation ou par sublimation de matériaux précurseurs
17.
METHOD FOR MANUFACTURING CARBON MONOXIDE OR ORGANIC COMPOUND
A method for manufacturing carbon monoxide or an organic compound, which includes electrolytically reducing carbon dioxide to obtain carbon monoxide or an organic compound in an electrolytic reduction apparatus having an anode, a cathode, and an electrolytic solution containing carbon dioxide. Carbon dioxide is selectively reduced into carbon monoxide or a specific organic compound by a potential to be applied to between the anode and the cathode.
KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (Japon)
THE DOSHISHA (Japon)
SENJU PHARMACEUTICAL CO., LTD. (Japon)
Inventeur(s)
Koizumi, Noriko
Okumura, Naoki
Kinoshita, Shigeru
Abrégé
The present invention provides medicaments for treating or preventing a disease, disorder, or condition associated with extracellular matrix (ECM) abnormality in a corneal endothelium, wherein the medicaments comprise a TGF-beta signal inhibiting agent. More specifically, this disease, disorder, or condition is a disorder associated with Fuchs' endothelial corneal dystrophy. Such a disorder includes photophobia, blurred vision, vision disorder, eye pain, lacrimation, hyperemia, pain, bullous keratopathy, ophthalmic unpleasantness, a decrease in contrast, glare, edema in corneal stroma, bullous keratopathy, corneal opacity, and the like. A preferable TGF-beta signal inhibiting agent includes 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide.
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/4725 - Isoquinoléines non condensées, p. ex. papavérine contenant d'autres hétérocycles
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
A61K 31/4402 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 2, p. ex. phéniramine, bisacodyl
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
19.
CORNEAL ENDOTHELIAL CELL PREPARATION CONTAINING NO CULTURE-DERIVED COMPONENT, AND METHOD FOR PRODUCING SAME
The present disclosure provides: a method for washing corneal endothelial cells; and a method for producing a corneal endothelial cell preparation. In one aspect, the present disclosure provides a method for producing a corneal endothelial cell preparation, the method comprising a step for washing a corneal endothelial cell or a corneal endothelium-like cell with a solution containing about 0.01% by weight to about 10% by weight of a protein and a step for mixing the corneal endothelial cell or the corneal endothelium-like cell with a composition for preparation production use to produce a corneal endothelial cell preparation, in which the protein is selected from the group consisting of human serum albumin, casein, lactoferrin, ovalbumin and combinations thereof.
Provided are an energy usage system with which it is possible to reduce carbon dioxide and obtain a carbon-containing material while suppressing release of carbon dioxide, and a method for manufacturing a carbon-containing material. The energy usage system (201) is provided with a circulation circuit (230) through which water circulates, the circulation circuit (230) having a pump (232) for intaking and pumping water, a waste heat boiler (236) for heating the water using energy obtained by waste heat, an electrolytic reduction device (70) for heating an electrolytic solution using the heat of the water, and a generator (20).
C25B 9/00 - Cellules ou assemblages de cellulesÉléments de structure des cellulesAssemblages d'éléments de structure, p. ex. assemblages d'électrode-diaphragmeCaractéristiques des cellules relatives aux procédés
C25B 9/67 - Moyens de chauffage ou de refroidissement
F01D 15/00 - Adaptations des "machines" ou machines motrices à des usages particuliersCombinaisons des machines motrices avec les dispositifs qu'elles entraînent
F22B 1/02 - Méthodes de production de vapeur caractérisées par le genre de chauffage par exploitation de l'énergie thermique contenue dans une source chaude
F25B 1/00 - Machines, installations ou systèmes à compression à cycle irréversible
F25B 11/02 - Machines, installations ou systèmes à compression utilisant des turbines, p. ex. des turbines à gaz comme détendeurs
F25B 27/02 - Machines, installations ou systèmes utilisant des sources d'énergie particulières utilisant la chaleur perdue, p. ex. chaleur dégagée par des moteurs à combustion interne
21.
S100A8-INHIBITING PEPTIDE AND DISEASE THERAPEUTIC AGENT CONTAINING SAME
S100A8-inhibiting peptides include (A) a peptide of 5 to 10 residues in length containing a fifth alanine (Ala) from an N-terminus in an amino acid sequence of SEQ ID NO: 1, or (B) a peptide consisting of an amino acid sequence of SEQ ID NO: 2.
In a case where an alkali aqueous solution is used as an electrolyte, provided are an oxygen catalyst excellent in catalytic activity and composition stability, an electrode having high activity and stability using this oxygen catalyst, and an electrochemical measurement method that can evaluate the catalytic activity of the oxygen catalyst alone. The oxygen catalyst is an oxide having peaks at positions of 2θ=30.07°±1.00°, 34.88°±1.00°, 50.20°±1.00°, and 59.65°±1.00° in an X-ray diffraction measurement using a CuKα ray, and having constituent elements of bismuth, ruthenium, sodium, and oxygen. An atom ratio O/Bi of oxygen to bismuth and an atom ratio O/Ru of oxygen to ruthenium are both more than 3.5.
H01M 4/90 - Emploi de matériau catalytique spécifié
C25B 11/063 - Métal valve, c.-à-d. dont l’oxyde est semi-conducteur, p. ex. titane
C25B 11/091 - Électrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau électro-catalytique formé d’au moins un élément catalytique et d’au moins un composé catalytiqueÉlectrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau électro-catalytique formé de plusieurs éléments catalytiques ou composés catalytiques
H01M 12/04 - Éléments hybridesLeur fabrication composés d'un demi-élément du type élément à combustible et d'un demi-élément du type élément primaire
23.
CARBON CARRIER FOR FUEL CELL CATALYST AND FUEL CELL CATALYST
Realized are a carbon support for a fuel cell catalyst and a catalyst for a fuel cell which have excellent durability and excellent catalytic activity when a catalyst metal is supported. A carbon support according to an embodiment of the present invention has diffraction peaks of a (002) plane which are observed at least at 2? = 22.5° to 25°, 26°, and 26.5° in an X-ray diffraction spectrum with CuK? rays, has an intensity ratio I(P1)/I(P2) between a peak P1 at 2? = 26° and a peak P2 at 2? = 26.5° of not less than 1.4, and has a BET specific surface area of not less than 1000 m2/g.
B01J 35/10 - Catalyseurs caractérisés par leur forme ou leurs propriétés physiques, en général solides caractérisés par leurs propriétés de surface ou leur porosité
H01M 4/90 - Emploi de matériau catalytique spécifié
The present invention realizes a carbon carrier for a fuel cell catalyst and a fuel cell catalyst, having excellent durability and catalytic activity when carrying a catalyst metal. A carbon carrier according to one embodiment of the present invention is such that, in the X-ray diffraction spectrum using CuKα rays, diffraction peaks of a (002) plane are observed at at least 2θ = 22.5° to 25°, 26°, and 26.5°, the intensity ratio I(P1)/I(P2) of a peak P1 at 2θ = 26° to a peak P2 at 2θ = 26.5° is 1.4 or more, and the BET specific surface area is 1000 m2/g or more.
B01J 35/10 - Catalyseurs caractérisés par leur forme ou leurs propriétés physiques, en général solides caractérisés par leurs propriétés de surface ou leur porosité
The present disclosure provides a method for cryopreserving corneal endothelial cells and/or corneal-endothelial-like cells, and a freezing preparation for corneal endothelial cells and/or corneal-endothelial-like cells. The present disclosure provides a method for preserving corneal endothelial cells and/or corneal-endothelial-like cells, wherein the method includes: a freezing step for freezing unfrozen corneal endothelial cells and/or corneal-endothelial-like cells, the freezing step including at least one stage in which the temperature is reduced at a rate of less than 1°C/min when the temperature is changed from the unfrozen temperature to the freezing target temperature; and, if necessary, a step for maintaining the corneal endothelial cells and/or corneal-endothelial-like cells in a frozen state.
C25B 9/00 - Cellules ou assemblages de cellulesÉléments de structure des cellulesAssemblages d'éléments de structure, p. ex. assemblages d'électrode-diaphragmeCaractéristiques des cellules relatives aux procédés
The present disclosure provides a method for cryopreserving corneal endothelial cells and/or corneal-endothelial-like cells, and a freezing preparation for corneal endothelial cells and/or corneal-endothelial-like cells. The present disclosure provides a method for preserving corneal endothelial cells and/or corneal-endothelial-like cells, wherein the method includes: a freezing step for freezing unfrozen corneal endothelial cells and/or corneal-endothelial-like cells, the freezing step including at least one stage in which the temperature is reduced at a rate of less than 1°C/min when the temperature is changed from the unfrozen temperature to the freezing target temperature; and, if necessary, a step for maintaining the corneal endothelial cells and/or corneal-endothelial-like cells in a frozen state.
The present invention addresses the problem of providing a detoxifying agent and a detoxifying agent kit both for detoxifying CO and HCN in a living body simultaneously. Provided is a detoxifying agent for removing carbon monoxide and hydrogen cyanide from a body, the detoxifying agent being characterized by containing, as active ingredients, a first inclusion complex having such a structure that a first cyclodextrin dimer represented by general formula (1) includes a first water-soluble metal porphyrin having a bivalent central metal and a second inclusion complex having such a structure that a second cyclodextrin dimer represented by general formula (2) includes a first water-soluble metal porphyrin having a bivalent central metal, and also characterized by further containing a reducing agent if necessary (In formulae (1) and (2), R represents a protective group protecting a hydroxyl group of the cyclodextrin, m and p each represent an integer of 1 or 2, and n and q each represent an integer of 1-3.).
A61K 31/555 - Composés hétérocycliques contenant des métaux lourds, p. ex. hémine, hématine, mélarsoprol
A61K 31/409 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil ayant quatre de ces cycles, p. ex. dérivés de la porphine, bilirubine, biliverdine
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
This anode structure (10) for a secondary battery has a main portion (12) in the form of a foil or a thin plate containing zinc as a base material, and an non-electron-conductive film (11) located on at least one surface of the main portion (12). The film (11) has elastic properties. The film (11) is provided with an opening (13) formed such that a part of a surface of the main portion (12) is exposed, and an electrode reaction inhibiting portion (14) that surrounds the opening (13) and inhibits an electrode reaction of the main portion (12). The film (11) is bonded to the main portion (12) in a liquid-tight manner.
H01M 50/474 - Éléments d'espacement à l'intérieur des cellules autres que les séparateurs, les membranes ou les diaphragmesLeurs procédés de fabrication caractérisés par leur position dans les cellules
H01M 50/477 - Éléments d'espacement à l'intérieur des cellules autres que les séparateurs, les membranes ou les diaphragmesLeurs procédés de fabrication caractérisés par leur forme
H01M 50/48 - Éléments d'espacement à l'intérieur des cellules autres que les séparateurs, les membranes ou les diaphragmesLeurs procédés de fabrication caractérisés par le matériau
30.
METHOD FOR PRODUCING METAL CARBIDE, METHOD FOR PRODUCING HYDROCARBON, AND METAL CARBIDE COMPOSITION
Provided are: a method for producing a metal carbide using carbon dioxide as a carbon source and a metal oxide as a metal source; a method for producing a hydrocarbon from the metal carbide obtained using carbon dioxide as a carbon source and a metal oxide as a metal source; and a metal carbide composition. This method for producing a metal carbide includes: preparing a molten salt containing a first metal oxide; adding carbon dioxide to the molten salt; applying voltage to the molten salt containing the carbon dioxide; and obtaining a precipitate containing a carbide of the first metal. Furthermore, this method for producing a hydrocarbon includes hydrolyzing a carbide of the first metal so as to obtain a hydrocarbon-containing gas and a hydroxide of the first metal.
C07C 1/32 - Préparation d'hydrocarbures à partir d'un ou plusieurs composés, aucun d'eux n'étant un hydrocarbure à partir de composés renfermant des hétéro-atomes autres que l'oxygène ou les halogènes, ou en addition à ceux-ci
Provided are a method for producing a metal carbide using a metal carbonate as a metal source, a method for producing a hydrocarbon from a metal carbide obtained using a metal carbonate as a metal source, and a metal carbide composition. Provided is a method for producing a metal carbide, the method including preparing a molten salt including a carbonate of a first metal, and applying a voltage to the molten salt to obtain a precipitate including a carbide of the first metal. Also provided is a method for producing a hydrocarbon, the method including hydrolyzing the carbide of a first metal to obtain a hydrocarbon and a hydroxide of the first metal.
C07C 1/32 - Préparation d'hydrocarbures à partir d'un ou plusieurs composés, aucun d'eux n'étant un hydrocarbure à partir de composés renfermant des hétéro-atomes autres que l'oxygène ou les halogènes, ou en addition à ceux-ci
There are provided a method for predicting a springback amount and a method for bending a deformed reinforcing bar including: supplying the deformed reinforcing bar bending the supplied deformed reinforcing bar, and subsequently measuring a first bending angle in a state of releasing a bending force on the deformed reinforcing bar; further bending the reinforcing bar from which the bending force has been released, and subsequently measuring a second bending angle in a state of releasing the bending force; and predicting a relationship between the bending angle and the springback amount by using the measurement results after executing the further bending once or a plurality of times, in which the bending angle is greater for subsequent steps.
G01N 3/20 - Recherche des propriétés mécaniques des matériaux solides par application d'une contrainte mécanique en appliquant des efforts permanents de flexion
G01N 3/06 - Adaptations particulières des moyens d'indication ou d'enregistrement
H04B 7/08 - Systèmes de diversitéSystèmes à plusieurs antennes, c.-à-d. émission ou réception utilisant plusieurs antennes utilisant plusieurs antennes indépendantes espacées à la station de réception
34.
MTOR-INHIBITOR-CONTAINING MEDICINE FOR TREATING OR PREVENTING OPHTHALMIC SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION THEREOF
The present invention provides a medicine and a method for preventing or treating ophthalmic symptoms, disorders, or diseases. The present invention provides an mTOR-inhibitor-containing composition for preventing or treating ophthalmic symptoms, disorders, or diseases. In some of the embodiments of the present invention, this composition is capable of treating or preventing corneal endothelial symptoms, disorders, or diseases; in particular, corneal endothelial symptoms, disorders, or diseases that are attributed to overexpression of the transforming growth factor-β (TGF-β) signal and/or extracellular matrix (ECM).
A61K 31/711 - Acides désoxyribonucléiques naturels, c.-à-d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
35.
Liquid Flow Formation Method and Object Moving Method Using Same
The present disclosure provides a method for forming a liquid flow in a surface region of a liquid, and a method for moving a larger object in a non-contact and non-invasive manner.
B01J 19/12 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaireAppareils à cet usage utilisant des radiations électromagnétiques
B82Y 15/00 - Nanotechnologie pour l’interaction, la détection ou l'actionnement, p. ex. points quantiques comme marqueurs en dosages protéiques ou moteurs moléculaires
B82Y 40/00 - Fabrication ou traitement des nanostructures
36.
Receiver apparatus, and method for producing parameters for demodulation
A method implemented in a computer system includes training a network, which is obtained by unfolding an iterative algorithm for demodulation or demodulation and decoding, using a machine learning technique with a loss function that takes into account non-Gaussianity of a log-likelihood ratio (LLR) distribution calculated from an output of the network. The method further includes producing a first set of learned parameters of that iterative algorithm.
Provided is a metal negative electrode used for a secondary battery. The metal negative electrode includes an active material portion, a current collector, and a non-electronically conductive reaction space divider. The active material portion forms metal during charging and forms an oxidation product of the metal during discharging. The metal is used as a negative-electrode active material. The current collector is electrically connected to the active material portion. The non-electronically conductive reaction space divider is integrally formed with or connected to the current collector and/or the active material portion. The reaction space divider has a plurality of electrolyte holder portions configured to hold a liquid electrolyte.
H01M 4/46 - Alliages à base de magnésium ou d'aluminium
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p. ex. batteries à insertion ou intercalation de lithium dans les deux électrodesBatteries à l'ion lithium
H01M 10/054 - Accumulateurs à insertion ou intercalation de métaux autres que le lithium, p. ex. au magnésium ou à l'aluminium
H01M 4/02 - Électrodes composées d'un ou comprenant un matériau actif
38.
THERAPEUTIC DRUG FOR DISEASES RELATED TO ENDOPLASMIC RETICULUM CELL DEATH IN CORNEAL ENDOTHELIUM
Kyoto Prefectural Public University Corporation (Japon)
The Doshisha (Japon)
Senju Pharmaceutical Co., Ltd. (Japon)
Inventeur(s)
Koizumi, Noriko
Okumura, Naoki
Kinoshita, Shigeru
Abrégé
The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress. Specifically, the present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress in the corneal epithelium, the drug containing a TGFβ-signal inhibitor. As a preferred TGFβ-signal inhibitor, the drug contains 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridinyl)-1H-imidazole-2-yl]benzamide.
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
The present disclosure provides a method for producing a carbon material, wherein a carbon material is obtained by electrolytically reducing carbon dioxide in an electrolytic reduction apparatus that comprises an anode electrode, a cathode electrode and an electrolyte solution that contains carbon dioxide. With respect to this method for producing a carbon material, the electrolyte solution contains an ionic liquid.
C25B 9/00 - Cellules ou assemblages de cellulesÉléments de structure des cellulesAssemblages d'éléments de structure, p. ex. assemblages d'électrode-diaphragmeCaractéristiques des cellules relatives aux procédés
C25B 11/04 - ÉlectrodesLeur fabrication non prévue ailleurs caractérisées par le matériau
C25B 15/02 - Commande ou régulation des opérations
40.
METHOD FOR MANUFACTURING CARBON MONOXIDE OR ORGANIC COMPOUND
The present invention provides a method for manufacturing carbon monoxide or an organic compound in which carbon dioxide is electrolytically reduced and carbon monoxide or the organic compound is obtained in an electrolytic reduction device having an anode electrode, a cathode electrode, and an electrolytic solution containing carbon dioxide, wherein said method for manufacturing carbon monoxide or an organic compound comprises the electrolytic solution containing an ionic liquid and water.
C25B 9/00 - Cellules ou assemblages de cellulesÉléments de structure des cellulesAssemblages d'éléments de structure, p. ex. assemblages d'électrode-diaphragmeCaractéristiques des cellules relatives aux procédés
C25B 11/02 - ÉlectrodesLeur fabrication non prévue ailleurs caractérisées par la configuration ou la forme
C25B 11/04 - ÉlectrodesLeur fabrication non prévue ailleurs caractérisées par le matériau
C25B 11/042 - Électrodes à base d’un seul matériau
A varifocal gel lens 1 comprising an annular ultrasonic transducer 3, a transparent and elastic lens 4, and a drive unit 5 that applies an electric signal to the ultrasonic transducer 3 to generate an ultrasonic wave is characterized in that the ultrasonic transducer 3 includes four electrodes 31 to 34 divided into N in the circumferential direction, and the drive unit 5 has a traveling wave mode in which electric signals of different phases that increase or decrease in the circumferential direction are applied to the four electrodes 31 to 34 and an ultrasonic wave propagating in the circumferential direction of the lens 4 is generated to raise a peripheral portion of the lens 4.
[Problem] To provide a gold-supported carbon catalyst in which the size of gold fine particles is reduced and the strength of adhesion thereof to carbon black is increased, and aggregation of gold fine particles can be suppressed. [Solution] A gold-supported carbon catalyst in which alkanethiol is coordinated with a coverage factor of 10-70%, and gold fine particles having an average particle diameter of 1.0-1.5 nm are supported on carbon black.
B22F 9/00 - Fabrication des poudres métalliques ou de leurs suspensionsAppareils ou dispositifs spécialement adaptés à cet effet
B22F 9/24 - Fabrication des poudres métalliques ou de leurs suspensionsAppareils ou dispositifs spécialement adaptés à cet effet par un procédé chimique avec réduction de mélanges métalliques à partir de mélanges métalliques liquides, p. ex. de solutions
The present invention provides: an electrode which is used for oxygen reactions and which is excellent in catalyst activity and stability; a method for preparing the electrode; and an electrochemical device using the electrode. This electrode is provided with an oxide, as an oxygen catalyst, which has peaks at positions of 2? = 30.07° ± 1.00°, 34.88° ± 1.00°, 50.20° ± 1.00° and 59.65° ± 1.00° in X-ray diffraction measurements using CuK? rays and which contains, as constituent elements, bismuth, ruthenium, sodium and oxygen.
C25B 11/073 - Électrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau électro-catalytique
H01M 12/06 - Éléments hybridesLeur fabrication composés d'un demi-élément du type élément à combustible et d'un demi-élément du type élément primaire avec une électrode métallique et une électrode à gaz
H01M 12/08 - Éléments hybridesLeur fabrication composés d'un demi-élément du type élément à combustible et d'un demi-élément du type à élément secondaire
44.
ELECTRODE, METHOD FOR PREPARING SAID ELECTRODE, AND ELECTROCHEMICAL DEVICE USING SAID ELECTRODE
The present invention provides: an electrode which is used for oxygen reactions and which is excellent in catalyst activity and stability; a method for preparing the electrode; and an electrochemical device using the electrode. This electrode is provided with an oxide, as an oxygen catalyst, which has peaks at positions of 2θ = 30.07° ± 1.00°, 34.88° ± 1.00°, 50.20° ± 1.00° and 59.65° ± 1.00° in X-ray diffraction measurements using CuKα rays and which contains, as constituent elements, bismuth, ruthenium, sodium and oxygen.
H01M 12/06 - Éléments hybridesLeur fabrication composés d'un demi-élément du type élément à combustible et d'un demi-élément du type élément primaire avec une électrode métallique et une électrode à gaz
H01M 12/08 - Éléments hybridesLeur fabrication composés d'un demi-élément du type élément à combustible et d'un demi-élément du type à élément secondaire
H01M 4/38 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'éléments simples ou d'alliages
C25B 11/073 - Électrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau électro-catalytique
C25B 9/00 - Cellules ou assemblages de cellulesÉléments de structure des cellulesAssemblages d'éléments de structure, p. ex. assemblages d'électrode-diaphragmeCaractéristiques des cellules relatives aux procédés
45.
OXYGEN CATALYST AND ELECTRODE USING SAID OXYGEN CATALYST
Provided are: an oxygen catalyst that uses an alkaline aqueous solution as an electrolyte and has high catalytic activity; and an electrode. The oxygen catalyst according to the present invention is an oxygen catalyst in which an alkaline aqueous solution is used as an electrolyte, the oxygen catalyst being characterized by having a pyrochlore oxide structure including bismuth on an A-site and ruthenium on a B-site, and containing manganese as well as bismuth and ruthenium. The electrode according to the present invention is characterized by using the oxygen catalyst according to the present invention.
The present disclosure provides a composition for enhancing the therapeutic effect of cell injection therapy, said therapy aiming at treating or preventing a corneal endothelial symptom, disorder or disease. In one embodiment, the present disclosure provides a composition, which comprises a ROCK inhibitor, for enhancing the therapeutic effect of cell injection therapy, said therapy aiming at treating or preventing a corneal endothelial symptom, disorder or disease of a subject. This composition, which is to be used in combination with corneal endothelial cells and/or corneal endothelial-like cells, is characterized in that the composition is administered prior to the injection of the corneal endothelial cells and/or corneal endothelial-like cells into the anterior chamber of the subject. In some embodiments, the composition, etc. of the present disclosure are formulated into eye-drops.
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 31/4409 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 4, p. ex. isoniazide, iproniazide
A61K 31/472 - Isoquinoléines non condensées, p. ex. papavérine
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p. ex. clozapine, dilazèpe
The present disclosure provides a method for preserving corneal endothelial cells. The present disclosure provides a method for preserving a suspension of corneal endothelial cells and/or corneal endothelium-like cells, the method including a step for preserving the corneal endothelial cells and/or corneal endothelium-like cells accommodated in a vessel while shaking the same for at least a certain time. In some embodiments, shaking may be reciprocal shaking, giratory shaking, horizontal eccentric shaking, wave-shape (seesaw) shaking, figure-of-eight shaking, or rotary shaking.
1355 (third period) continuously passed in which variation was less than or equal to a threshold value γ (third threshold value). If data extraction parameters including each of these determinations are satisfied, the data extraction unit 23 extracts data regarding this transient reponse time from a storage unit 22.
A S100A8-inhibiting peptide comprises (A) a peptide which comprises a portion of the amino acid sequence represented by SEQ ID NO: 1, contains an alanine (Ala) residue located at position-5 from the N-terminal of the aforementioned amino acid sequence, and has a length composed of 5 to 10 residues or (B) a peptide which comprises the amino acid sequence represented by SEQ ID NO: 2.
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 25/18 - Antipsychotiques, c.-à-d. neuroleptiquesMédicaments pour le traitement de la manie ou de la schizophrénie
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 31/14 - Antiviraux pour le traitement des virus ARN
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
Provided are: an oxygen catalyst having excellent catalytic activity and composition stability in the case of using an alkaline aqueous solution as an electrolyte; an electrode having high activity and stability using said oxygen catalyst; and an electrochemical measurement method that can evaluate the catalytic activity of an oxygen catalyst alone. The oxygen catalyst is an oxide that has peaks at the positions of 2θ=30.07°±1.00°, 34.88°±1.00°, 50.20°±1.00°, and 59.65°±1.00° in X-ray diffraction measurements using CuKα-rays and that contains, as constituent elements, bismuth, ruthenium, sodium, and oxygen, wherein both the atomic ratio O/Bi of oxygen to bismuth and the atomic ratio O/Ru of oxygen to ruthenium are greater than 3.5.
H01M 12/06 - Éléments hybridesLeur fabrication composés d'un demi-élément du type élément à combustible et d'un demi-élément du type élément primaire avec une électrode métallique et une électrode à gaz
H01M 12/08 - Éléments hybridesLeur fabrication composés d'un demi-élément du type élément à combustible et d'un demi-élément du type à élément secondaire
H01M 4/86 - Électrodes inertes ayant une activité catalytique, p. ex. pour piles à combustible
H01M 4/90 - Emploi de matériau catalytique spécifié
C25B 11/073 - Électrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau électro-catalytique
G01N 27/30 - Électrodes, p. ex. électrodes pour testsDemi-cellules
G01N 27/48 - Systèmes utilisant la polarographie, c.-à-d. la mesure des variations d'intensité sous une tension qui varie lentement
A computer system includes at least one memory and at least one processor coupled to the at least one memory and configured to execute one or more sets of instructions. The one or more sets of instructions, when executed by the at least one processor, cause the computer system to provide virtualized radio access network functions including executing a BP algorithm and provide controller functions including adjusting the total number of iterations of the BP algorithm depending on available computing resources of the computer system.
A BP detector of a wireless receiver apparatus reads a first parameter set or a second parameter set. The first parameter set includes a plurality of scaling factors and a plurality of damping factors learned together using a deep learning technique. The second parameter set includes a plurality of scaling factors and a plurality of node selection factors learned together using a deep learning technique from a memory. The BP detector executes an iterative BP algorithm that uses the first parameter set or the second parameter set in order to perform multi-user detection.
H04L 1/00 - Dispositions pour détecter ou empêcher les erreurs dans l'information reçue
H03M 13/11 - Détection d'erreurs ou correction d'erreurs transmises par redondance dans la représentation des données, c.-à-d. mots de code contenant plus de chiffres que les mots source utilisant un codage par blocs, c.-à-d. un nombre prédéterminé de bits de contrôle ajouté à un nombre prédéterminé de bits d'information utilisant plusieurs bits de parité
The present disclosure provides a formulation having improved solubility and/or stability of emricasan. In one embodiment, the present disclosure provides a formulation containing (i) emricasan or a derivative thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, (ii) a nonionic surfactant including a polyoxyethylene group, and (iii) a buffering agent that maintains the pH at about 4.5 to about 8.5. The present disclosure also provides a composition in the form of powder for preparing such a formulation at the time of use.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
54.
ZINC NEGATIVE ELECTRODE AND MANUFACTURING METHOD THEREFOR, AND SECONDARY CELL COMPRISING SAID ZINC NEGATIVE ELECTRODE AND MANUFACTURING METHOD THEREFOR
Provided are: a zinc negative electrode having exceptional repeating resistance, and excellent charge/discharge cycling characteristics even at a high charge/discharge rate; a manufacturing method therefor; a secondary cell using the zinc negative electrode; and a manufacturing method therefor. A zinc negative electrode used in a secondary cell, wherein the zinc negative electrode comprises: an active material part in which zinc is generated during charging, and oxidized zinc is generated during discharging, the zinc being used as a negative electrode active material; a collector that is electrically connected to the active material part; and a non-electron-conductive reaction space restriction part that is integrally formed with or connected to the collector and/or the active material part. The reaction space restriction part has a plurality of electrolyte-holding parts comprising a space that can hold a liquid electrolyte.
H01M 4/90 - Emploi de matériau catalytique spécifié
H01M 12/08 - Éléments hybridesLeur fabrication composés d'un demi-élément du type élément à combustible et d'un demi-élément du type à élément secondaire
55.
CARBON MONOXIDE QUANTIFICATION METHOD AND CARBON MONOXIDE MEASUREMENT KIT
Proposed are a carbon monoxide quantification method and a carbon monoxide measurement kit, whereby it becomes possible to measure a trace amount of carbon monoxide contained in blood or a tissue with high accuracy in a simple manner without the need to use a carbon monoxide gas that is harmful to the human body. A method for quantifying carbon monoxide contained in a sample, the method comprising the steps of: using the sample and an inclusion complex for quantification use in which a cyclodextrin dimer includes a water-soluble metal porphyrin to prepare an aqueous inclusion complex solution containing, as substances derived from the inclusion complex for quantification use, only a deoxy inclusion complex (II) which has a bivalent center metal and is not bonded to oxygen or carbon monoxide and a CO-bonded inclusion complex (II) which is produced as the result of the bonding of the deoxy inclusion complex (II) with carbon monoxide in the sample; measuring an ultraviolet-visible absorption spectrum of the inclusion complex solution; and calculating the quantity of carbon monoxide in the sample in accordance with a formula established based on the Lambert–Beer law employing each of a first inflection point observed at a wavelength of around 422 nm and a second inflection point observed at a wavelength of around 434 nm in the ultraviolet-visible absorption spectrum obtained by the above-mentioned measurement.
G01N 31/00 - Recherche ou analyse des matériaux non biologiques par l'emploi des procédés chimiques spécifiés dans les sous-groupesAppareils spécialement adaptés à de tels procédés
G01N 33/483 - Analyse physique de matériau biologique
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
56.
Caspase inhibitor-containing drug for treating or preventing disorders caused by TGF-β, and applications thereof
Provided is a drug or method for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by transforming growth factor-β (TGF-β) signals and/or mitochondrial abnormalities in corneal endothelial cells. The present invention provides a drug which includes caspase inhibitors, and which is for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by TGF-β signals and/or mitochondrial abnormalities in corneal endothelial cells. In the preferred embodiment, the condition, disorder, or disease of the corneal endothelium is Fuchs' corneal endothelial dystrophy.
A61K 31/122 - Cétones ayant l'atome d'oxygène lié directement à un cycle, p. ex. quinones, vitamine K1, anthraline
A61K 31/4725 - Isoquinoléines non condensées, p. ex. papavérine contenant d'autres hétérocycles
A61K 31/165 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
2. Accordingly to the present invention, corneal endothelial cells can be preserved at a high cell survival rate. Corneal endothelial cells preserved in this manner have functions of normal corneal endothelial cells. Such cells can also be used as cells for treating a corneal endothelial disease or the like.
Provided is a method for efficiently producing an epoxy compound using an electrochemical method. This method for producing an epoxy compound comprises electrically oxidizing a salt represented by formula (a) in an aqueous phase to yield a peracid ion represented by formula (b) and oxidizing an olefin with the yielded peracid ion represented by formula (b) to obtain a corresponding epoxy compound. In the formulae, Rd22, CO, and P(=O)OH and A+ represents a cation selected from among alkali metal, alkaline-earth metal, ammonium, phosphonium, and sulfonium ions.
C07D 301/12 - Synthèse du cycle de l'oxirane par oxydation de composés non saturés, ou de mélanges de composés non saturés et de composés saturés par le peroxyde d'hydrogène ou par des peroxydes ou peracides inorganiques
Provided is a method for moving a larger object in a contactless and non-invasive manner. In this method for forming a liquid flow at a surface region of a liquid, a laser beam (14) is emitted onto a specific surface region (18) of a dispersed microparticle-containing liquid (10) in which an object floats, thereby causing the temperature of the specific surface region of the liquid to be relatively higher than another neighboring surface region so as to form a temperature gradient between the two surface regions of the liquid.
B01J 19/12 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaireAppareils à cet usage utilisant des radiations électromagnétiques
B82Y 15/00 - Nanotechnologie pour l’interaction, la détection ou l'actionnement, p. ex. points quantiques comme marqueurs en dosages protéiques ou moteurs moléculaires
B82Y 40/00 - Fabrication ou traitement des nanostructures
60.
METAL NEGATIVE ELECTRODE, METHOD FOR FABRICATING THE SAME AND SECONDARY BATTERY INCLUDING THE SAME
Provided are: a metal negative electrode having exceptional repeating resistance, and excellent charge/discharge cycling characteristics even at a high charge/discharge rate; a method for manufacturing same; and a secondary cell in which the metal negative electrode is used. A metal negative electrode used in a secondary cell, wherein the metal negative electrode comprises: an active material part in which a metal is produced during charging and an oxidation product of the metal is produced during discharging, the metal being used as a negative electrode active material; a collector electrically connected to the active material part; and a non-electron-conductive reaction space restriction part integrally formed with or connected to the collector and/or the active material part. The reaction space restriction part has a plurality of electrolyte-holding parts capable of holding a liquid electrolyte.
H01M 50/477 - Éléments d'espacement à l'intérieur des cellules autres que les séparateurs, les membranes ou les diaphragmesLeurs procédés de fabrication caractérisés par leur forme
H01M 50/474 - Éléments d'espacement à l'intérieur des cellules autres que les séparateurs, les membranes ou les diaphragmesLeurs procédés de fabrication caractérisés par leur position dans les cellules
H01M 12/08 - Éléments hybridesLeur fabrication composés d'un demi-élément du type élément à combustible et d'un demi-élément du type à élément secondaire
61.
METAL NEGATIVE ELECTRODE, METHOD FOR MANUFACTURING METAL NEGATIVE ELECTRODE, AND SECONDARY CELL COMPRISING METAL NEGATIVE ELECTRODE
Provided are: a metal negative electrode having exceptional repeating resistance, and excellent charge/discharge cycling characteristics even at a high charge/discharge rate; a method for manufacturing same; and a secondary cell in which the metal negative electrode is used. A metal negative electrode used in a secondary cell, wherein the metal negative electrode comprises: an active material part in which a metal is produced during charging and an oxidation product of the metal is produced during discharging, the metal being used as a negative electrode active material; a collector electrically connected to the active material part; and a non-electron-conductive reaction space restriction part integrally formed with or connected to the collector and/or the active material part. The reaction space restriction part has a plurality of electrolyte-holding parts capable of holding a liquid electrolyte.
H01M 12/08 - Éléments hybridesLeur fabrication composés d'un demi-élément du type élément à combustible et d'un demi-élément du type à élément secondaire
H01M 4/02 - Électrodes composées d'un ou comprenant un matériau actif
Kyoto Prefectural Public University Corporation (Japon)
The Doshisha (Japon)
Inventeur(s)
Ikeda, Hanako
Kakizuka, Akira
Kinoshita, Shigeru
Nakamura, Takahiro
Nagata, Maho
Koizumi, Noriko
Okumura, Naoki
Abrégé
The inventors have found that VCP inhibitors protect corneal endothelial cells and corneal epithelial cells. Accordingly, the disclosure provides a composition for protecting a cornea comprising a compound of formula (I) or an ester, oxide, pharmaceutically acceptable salt or solvate thereof. In another aspect the disclosure provides a composition for treating and/or preventing a corneal disease comprising a compound of formula (I). In a further aspect the disclosure provides a composition for ocular irrigation comprising a compound of formula (I). In a still further aspect the disclosure provides a composition for preserving a corneal graft comprising a compound of formula (I).
Provided is a medicament or a method for treating or preventing a corneal endothelial condition, disorder or disease due to a transforming growth factor-β (TGF-β) signal in corneal endothelial cells using a p38 MAP kinase inhibitor (in particular AKP-001), such as a pyrimidinyl isoxazole derivative or a pyridyl isoxazole derivative. In a preferred embodiment, the corneal endothelial condition, disorder or disease due to the TGF-β signal is Fuchs' corneal endothelial dystrophy.
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
64.
Resin composition and method for determining flame retardancy of resin composition
C04B 35/563 - Produits céramiques mis en forme, caractérisés par leur compositionCompositions céramiquesTraitement de poudres de composés inorganiques préalablement à la fabrication de produits céramiques à base de non oxydes à base de carbures à base de carbure de bore
C04B 35/58 - Produits céramiques mis en forme, caractérisés par leur compositionCompositions céramiquesTraitement de poudres de composés inorganiques préalablement à la fabrication de produits céramiques à base de non oxydes à base de borures, nitrures ou siliciures
Provided is a novel compound capable of efficiently introducing CO into cells. The novel compound is represented by formula (A). In the formula, R represents hydrogen or an alkyl group which has 1-8 carbon atoms and optionally has a substituent such as a halogen atom or an aryl group.
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07F 13/00 - Composés contenant des éléments des groupes 7 ou 17 du tableau périodique
One aspect of the present invention is a nonaqueous electrolyte for an energy storage device comprising: an alkali metal salt; a first aprotic organic solvent coordinating to an alkali metal ion in the alkali metal salt, and not including a fluorine atom; a second aprotic organic solvent including a fluorine atom; and an additive comprising a polar group and a group including a fluorine atom, wherein a content of the alkali metal salt is no less than 0.9 mol/kg and less than 2 mol/kg, a content of the first aprotic organic solvent with respect to the content of the alkali metal salt in terms of a molar ratio is no less than 0.7 and no greater than 4, and a content of the second aprotic organic solvent with respect to a total amount of the first aprotic organic solvent, the second aprotic organic solvent and the additive is no less than 40% by volume.
H01M 10/0569 - Matériaux liquides caracterisés par les solvants
H01M 4/131 - Électrodes à base d'oxydes ou d'hydroxydes mixtes, ou de mélanges d'oxydes ou d'hydroxydes, p. ex. LiCoOx
H01M 4/36 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs
H01M 4/505 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de manganèse d'oxydes ou d'hydroxydes mixtes contenant du manganèse pour insérer ou intercaler des métaux légers, p. ex. LiMn2O4 ou LiMn2OxFy
H01M 4/525 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de nickel, de cobalt ou de fer d'oxydes ou d'hydroxydes mixtes contenant du fer, du cobalt ou du nickel pour insérer ou intercaler des métaux légers, p. ex. LiNiO2, LiCoO2 ou LiCoOxFy
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p. ex. batteries à insertion ou intercalation de lithium dans les deux électrodesBatteries à l'ion lithium
H01M 10/0567 - Matériaux liquides caracterisés par les additifs
H01M 4/02 - Électrodes composées d'un ou comprenant un matériau actif
68.
HYDROPHILIC POLYMER CROSSLINKED NETWORK HYDROGEL AND ACTIVE OXYGEN INHIBITOR
Provided is a novel hydrophilic polymer crosslinked network hydrogel. Also provided is an active oxygen inhibitor that senses ROS in a place where an excessive amount of ROS are present and releases an antioxidant. The hydrophilic polymer crosslinked network hydrogel comprises manganese tetrakis(4-carboxyphenyl)porphyrin and a linker L, said linker L having a polyethylene glycol chain linking manganese tetrakis(4-carboxyphenyl)porphyrin molecules to each other, and holds manganese tetrakis(4-carboxyphenyl)porphyrin within a network.
A61K 31/409 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil ayant quatre de ces cycles, p. ex. dérivés de la porphine, bilirubine, biliverdine
C08G 65/337 - Polymères modifiés par post-traitement chimique avec des composés organiques contenant d'autres éléments
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
Provided are: an oxygen catalyst that uses an alkaline aqueous solution as an electrolyte and has high catalytic activity; and an electrode. The oxygen catalyst according to the present invention is an oxygen catalyst in which an alkaline aqueous solution is used as an electrolyte, the oxygen catalyst being characterized by having a pyrochlore oxide structure including bismuth on an A-site and ruthenium on a B-site, and containing manganese as well as bismuth and ruthenium. The electrode according to the present invention is characterized by using the oxygen catalyst according to the present invention.
PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY (Japon)
Inventeur(s)
Akiyama, Iwaki
Tsujimoto, Yukako
Tanaka, Toshihiro
Hirai, Toshiko
Minamiguchi, Kiyoyuki
Abrégé
An ultrasound diagnostic device 100 determines the effects of cancer treatment on a specific site of a subject on the basis of ultrasonic echo signals reflected by the subject. The ultrasound diagnostic device 100 is provided with: a first probe 11 which emits ultrasonic waves to the subject and receives an echo signal; an operation unit 8 for receiving a selection operation for the position of a specific site from a user; a second probe 12 which emits ultrasonic waves to warm the specific site; and a control unit 5 which acquires thermal property information for the specific site on the basis of an echo signal acquired before warming the specific site with the ultrasonic waves emitted from the second probe and an echo signal acquired after warming, and determines the presence or absence of a contrast agent at the specific site on the basis of the thermal property information.
The present invention provides a medicine and a method for preventing or treating ophthalmic symptoms, disorders, or diseases. The present invention provides an mTOR-inhibitor-containing composition for preventing or treating ophthalmic symptoms, disorders, or diseases. In some of the embodiments of the present invention, this composition is capable of treating or preventing corneal endothelial symptoms, disorders, or diseases; in particular, corneal endothelial symptoms, disorders, or diseases that are attributed to overexpression of the transforming growth factor-β (TGF-β) signal and/or extracellular matrix (ECM).
A61K 31/711 - Acides désoxyribonucléiques naturels, c.-à-d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
72.
METHOD AND VESSEL FOR PRESERVING CORNEAL ENDOTHELIAL CELLS
The present disclosure provides a method for preserving corneal endothelial cells with a high cell survival rate. The present disclosure provides a method for preserving corneal endothelial cells and/or corneal endothelium-like cells, the method including a step for preserving the corneal endothelial cells and/or corneal endothelium-like cells in a vessel that has a bottom surface area of at least about 0.7 cm2. According to the present invention, corneal endothelial cells can be preserved with a high cell survival rate. The corneal endothelial cells preserved in this manner have the functions of healthy corneal endothelial cells, and can be used as therapeutic cells such as for corneal endothelial disease.
An ion analyzer that generates product ions from precursor ions derived from a sample component and analyzes the product ions includes a reaction chamber (2) into which the precursor ion is introduced, a radical generation chamber (51), a material gas supply source (52) configured to introduce material gas into the radical generation chamber (51), a vacuum evacuator (57) configured to evacuate the radical generation chamber (51), a vacuum discharge unit (53) configured to generate a vacuum discharge in the radical generation chamber (51), a radical irradiation unit (54) configured to irradiate an inside of the reaction chamber (2) with radicals generated from the material gas in the radical generation chamber (51), and a separation and detection (3) configured to separate and detect product ions generated from the precursor ion by reaction with the radicals according to at least one of a mass-to-charge ratio and ion mobility.
H01J 49/00 - Spectromètres pour particules ou tubes séparateurs de particules
H01J 49/04 - Dispositions pour introduire ou extraire les échantillons devant être analysés, p. ex. fermetures étanches au videDispositions pour le réglage externe des composants électronoptiques ou ionoptiques
The present disclosure provides a method for preserving corneal endothelial cells with a high cell survival rate. The present disclosure provides a method for preserving corneal endothelial cells and/or corneal endothelium-like cells, the method including a step for preserving the corneal endothelial cells and/or corneal endothelium-like cells in a vessel that has a bottom surface area of at least about 0.7 cm2. According to the present invention, corneal endothelial cells can be preserved with a high cell survival rate. The corneal endothelial cells preserved in this manner have the functions of healthy corneal endothelial cells, and can be used as therapeutic cells such as for corneal endothelial disease.
The present disclosure provides a composition and method for preserving ocular cells. More specifically, the present disclosure provides: a composition for preserving ocular cells, or culturing the same after preservation, the composition containing albumin and dimethyl sulfoxide; a cell preparation containing said ocular cells, albumin, and dimethyl sulfoxide; and a therapeutic/preventive method using the same. The present disclosure also provides a method for preserving corneal endothelial cells, the method including a step of suspending ocular cells in said composition to provide a suspension, and a step of freezing the suspension. In some embodiments, the ocular cells are corneal cells (for example, corneal endothelial cells).
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
Provided is a compound that specifically inhibits the production of Aβ protein and serves as an active component of a drug for treating and/or preventing Alzheimer's disease. The Aβ-protein-specific production inhibitor according to the present invention is characterized by containing a peptide (FGBTWDYWVYRRR, where B is an L-4,4'-biphenylalanine residue) that comprises an amino acid sequence set forth in SEQ ID NO: 1 and inhibits both β-secretase and γ-secretase activity. A peptide comprising the amino acid sequence set forth in SEQ ID NO: 1 can be utilized in the prevention and/or treatment of Alzheimer's disease.
A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
The present disclosure provides a formulation having improved solubility and/or stability of emricasan. In one embodiment, the present disclosure provides a formulation containing (i) emricasan or a derivative thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, (ii) a nonionic surfactant including a polyoxyethylene group, and (iii) a buffering agent that maintains the pH at about 4.5 to about 8.5. The present disclosure also provides a composition in the form of powder for preparing such a formulation at the time of use.
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
The present disclosure provides a formulation having improved solubility and/or stability of emricasan. In one embodiment, the present disclosure provides a formulation containing (i) emricasan or a derivative thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof, (ii) a nonionic surfactant including a polyoxyethylene group, and (iii) a buffering agent that maintains the pH at about 4.5 to about 8.5. The present disclosure also provides a composition in the form of powder for preparing such a formulation at the time of use.
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
Multi-screw kneader and method for producing nano-composite using said multi-screw kneader, and disk-shaped segment used for said kneader and said method
A multi-screw kneader is configured to exhibit an extensional flow function before and behind holes of a disk-shaped segment and a method for producing a nano-composite uses the multi-screw kneader. The multi-screw kneader includes a plurality of kneading screws and the disk-shaped segment in a barrel. The disk-shaped segment partitions the inside of the barrel downstream of a part for supplying a kneading material and includes shaft receiving parts through which rotating shafts of the kneading screws are to rotatably pass and the holes are defined in a periphery of the shaft penetrating parts and are configured to serve as flow channels of the kneading material. The method for producing the nano-composite includes charging nanoparticles as a resin additive using the multi-screw kneader.
B29B 7/48 - MélangeMalaxage continu, avec dispositifs mécaniques de mélange ou de malaxage avec dispositifs de mélange ou de malaxage mobiles rotatifs avec plus d'un arbre à dispositifs à engrènement, p. ex. à vis qui s'engrènent
An analytical device includes: a reaction unit into which an ion derived from a sample component is introduced; a radical generation unit that generates a radical by vacuum discharge and comprises a raw material introduction chamber into which a plasma raw material is introduced; a connection part that introduces the radical generated in the radical generation unit into a vacuum chamber, the vacuum chamber having a pressure lower than a pressure of the raw material introduction chamber and being connected to the reaction unit; and a separation unit that separates a generated ion generated by a reaction with the radical introduced via the connection part into the reaction unit according to m/z and/or ion mobility, wherein an inner diameter of a cross section of the connection part is equal to or less than 20 millimeters.
H01J 49/06 - Dispositifs électronoptiques ou ionoptiques
H01J 49/26 - Spectromètres de masse ou tubes séparateurs de masse
81.
CYCLONE REFRIGERATION DEVICE, CYCLONE COOLNESS/HEAT RECOVERY UNIT, AND HEAT PUMP SYSTEM PROVIDED WITH SAID CYCLONE REFRIGERATION DEVICE OR CYCLONE COOLNESS/HEAT RECOVERY UNIT
The present invention is provided with a cylinder part 1, an exhaust pipe 3, a cooling part 4 having a cavity 4a that passes through an internal space 1b of the cylinder part, a refrigerant inflow pipe 5, and a decompression device 6. A liquid-phase refrigerant that has been condensed under high pressure is supplied to a refrigerant supply pipe and is decompressed by the decompression device to form a solid-gas two-phase refrigerant. The solid-gas two-phase refrigerant flows into the internal space of the cylinder part and forms a downward spiral, and is separated into a solid-phase refrigerant S and a gas-phase refrigerant. The solid-phase refrigerant S accumulates in the cavity, and the gas-phase refrigerant forms an upward spiral passing from a bottom part of the cavity through the interior space inside the downward spiral and flows out from the exhaust pipe. The present invention is also provided with: pipelines 7a, 7b through which a fluid to be cooled circulates, said pipelines 7a, 7b through which a fluid to be cooled circulates extending through the cavity of the cooling part, and a fluid to be cooled from a cooling load 9 is circulated through the interior of the pipelines through which a fluid to be cooled circulates; a heat exchanger 8 provided to a portion of the pipelines through which a fluid to be cooled circulates that is within the cavity, the heat exchanger 8 performing heat exchange between the solid-phase refrigerant S and the fluid to be cooled; and a pump 10 that circulates the fluid to be cooled.
F25B 1/00 - Machines, installations ou systèmes à compression à cycle irréversible
F25B 7/00 - Machines, installations ou systèmes à compression fonctionnant en cascade, c.-à-d. avec plusieurs circuits, l'évaporateur d'un circuit refroidissant le condenseur du circuit suivant
F25D 3/12 - Dispositifs utilisant d'autres agents froidsDispositifs utilisant des récipients conservant le froid utilisant des gaz solidifiés, p. ex. de la neige carbonique
KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (Japon)
THE DOSHISHA (Japon)
Inventeur(s)
Ikeda, Hanako
Kakizuka, Akira
Kinoshita, Shigeru
Nakamura, Takahiro
Nagata, Maho
Koizumi, Noriko
Okumura, Naoki
Abrégé
The inventors discovered that a certain type of VCP inhibitor has a protective effect on corneal endothelial cells and corneal epithelial cells. Consequently, a composition for corneal protection is provided which contains the compound of expression (I) or an ester, oxide, pharmaceutically permissible salt or solvate thereof. As another embodiment, a pharmaceutical composition is provided for the treatment and/or prevention of corneal disease that contains the aforementioned compound. As a further embodiment, a composition for ocular perfusion containing the compound is provided. As yet a further embodiment, a composition for transplanted cornea preservation containing said compound is provided.
The present disclosure provides a composition for treating or preventing symptoms, disorders, or diseases of the corneal endothelium. The present invention specifically provides a composition which is for treating or preventing symptoms, disorders, or diseases of the corneal endothelium, and includes (T)EW-7197 (N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline), a derivative thereof, a pharmaceutically acceptable salt thereof, or a solvate of any of the foregoing.
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
Provided are a morbidity diagnosis support system, a morbidity diagnosis data-generating system, and a morbidity diagnosis support method that are capable of supporting a highly reliable morbidity diagnosis. A morbidity diagnosis support system includes an extension device for extending a tissue section of cells, an image-photographing device for acquiring image data by image-photographing the tissue section, an image analysis device for analyzing the image data to calculate an index of morbidity based on a mode of cracks generated in the tissue section by the extension, and an output device for outputting the calculated index.
G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G01N 1/28 - Préparation d'échantillons pour l'analyse
G01N 33/483 - Analyse physique de matériau biologique
85.
NONAQUEOUS ELECTROLYTE AND NONAQUEOUS ELECTROLYTE ELECTRICITY STORAGE ELEMENT
One embodiment of the present invention is a nonaqueous electrolyte for electricity storage elements, which contains an alkali metal salt, a first aprotic organic solvent that does not have a fluorine atom and is coordinated to an alkali metal ion which constitutes the alkali metal salt, a second aprotic organic solvent that has a fluorine atom, and an additive that has a polar group and a group having a fluorine atom. This nonaqueous electrolyte for electricity storage elements is configured such that: the content of the alkali metal salt is 0.9 mol/kg or more but less than 2 mol/kg; the content of the first aprotic organic solvent relative to the content of the alkali metal salt is from 0.7 to 4 (inclusive) in terms of the molar ratio; and the proportion of the content of the second aprotic organic solvent in the total content of the first aprotic organic solvent, the second aprotic organic solvent and the additive is 40% by volume or more.
H01M 10/0569 - Matériaux liquides caracterisés par les solvants
H01G 11/60 - Électrolytes liquides caractérisés par le solvant
H01G 11/62 - Électrolytes liquides caractérisés par le soluté, p. ex. sels, anions ou cations
H01G 11/64 - Électrolytes liquides caractérisés par les additifs
H01M 4/505 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de manganèse d'oxydes ou d'hydroxydes mixtes contenant du manganèse pour insérer ou intercaler des métaux légers, p. ex. LiMn2O4 ou LiMn2OxFy
H01M 4/525 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de nickel, de cobalt ou de fer d'oxydes ou d'hydroxydes mixtes contenant du fer, du cobalt ou du nickel pour insérer ou intercaler des métaux légers, p. ex. LiNiO2, LiCoO2 ou LiCoOxFy
Provided is a medicament or a method for treating or preventing a corneal endothelial condition, disorder or disease due to a transforming growth factor-.beta. (TGF-.beta.) signal in corneal endothelial cells using a p38 MAP kinase inhibitor (in particular AKP-001), such as a pyrimidinyl isoxazole derivative or a pyridyl isoxazole derivative. In a preferred embodiment, the corneal endothelial condition, disorder or disease due to the TGF-.beta. signal is Fuchs' corneal endothelial dystrophy.
Provided is a drug or a method that uses a p38 MAP kinase inhibitor (in particular AKP-001), such as a pyrimidinyl isoxazole derivative or a pyridyl isoxazole derivative, to treat or prevent a corneal endothelial condition, disorder or disease caused by transforming growth factor beta (TGF-β) signalling in corneal endothelial cells. In a preferred embodiment, the corneal endothelial condition, disorder or disease caused by TGF-β signalling is Fuchs corneal endothelial dystrophy.
Provided is a drug or method for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by transforming growth factor-β (TGF-β) signals, mitochondrial abnormalities, and/or endoplasmic reticulum (ER) associated stress in corneal endothelial cells, using p38 MAP kinase inhibitors. The present invention provides a drug which includes p38 MAP kinase inhibitors, and which is for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by TGF-β signals and/or mitochondrial abnormalities in corneal endothelial cells. In the preferred embodiment, the condition, disorder, or disease of the corneal endothelium is Fuchs' corneal endothelial dystrophy.
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
A61K 31/17 - Amides, p. ex. acides hydroxamiques ayant le groupe N-C(O)-N ou N-C(S)-N, p. ex. urée, thiourée, carmustine
A61K 31/4412 - Pyridines non condenséesLeurs dérivés hydrogénés ayant des groupes oxo liés directement à l'hétérocycle
A61K 31/4418 - Pyridines non condenséesLeurs dérivés hydrogénés ayant un carbocycle lié directement à l'hétérocycle, p. ex. cyproheptadine
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
89.
MTOR-INHIBITOR-CONTAINING MEDICINE FOR TREATING OR PREVENTING OPHTHALMIC SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION THEREOF
The present invention provides a medicine and a method for preventing or treating ophthalmic symptoms, disorders, or diseases. The present invention provides an mTOR-inhibitor-containing composition for preventing or treating ophthalmic symptoms, disorders, or diseases. In some of the embodiments of the present invention, this composition is capable of treating or preventing corneal endothelial symptoms, disorders, or diseases; in particular, corneal endothelial symptoms, disorders, or diseases that are attributed to overexpression of the transforming growth factor-.beta. (TGF-.beta.) signal and/or extracellular matrix (ECM).
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
The present invention provides a medicine and a method for preventing or treating ophthalmic symptoms, disorders, or diseases. The present invention provides an mTOR-inhibitor-containing composition for preventing or treating ophthalmic symptoms, disorders, or diseases. In some of the embodiments of the present invention, this composition is capable of treating or preventing corneal endothelial symptoms, disorders, or diseases; in particular, corneal endothelial symptoms, disorders, or diseases that are attributed to overexpression of the transforming growth factor-β (TGF-β) signal and/or extracellular matrix (ECM).
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 31/711 - Acides désoxyribonucléiques naturels, c.-à-d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
The present invention provides a method for screening for a compound that is effective against disorders of the corneal endothelium. The method according to the present invention comprises: (a) a step for bringing candidate compounds into contact with immortalized cells of Fuchs' corneal endothelial dystrophy in the presence of transforming growth factor (TGF)-β, making evaluations on the inhibitory activity of said candidate compounds against said TGF-β, and selecting a compound having the inhibitory activity; (b) a step for evaluating the toxicity of the compound selected in step (a) with respect to said immortalized cells; (c) a step for evaluating the inhibitory activity of the compound selected in step (a) against said TGF-β; and (d) a step for selecting a compound that has been evaluated to have low toxicity to said immortalized cells in step (b) and has been evaluated to have inhibitory activity against said TGF-β in step (c). The method according to the present invention makes it possible to screen for a compound that is effective for disorders of the corneal endothelium.
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
COMPOUNDS HAVING CASPASE INHIBITORY ACTIVITY, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS AND FOR TREATING OR PREVENTING CORNEAL ENDOTHELIAL SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION OF SAID PHARMACEUTICAL AGENT
The present invention provides a composition for treating or preventing corneal endothelial symptoms, disorders, or diseases that are attributed to TGF-β signaling in corneal endothelial cells. Provided by the present invention is a composition that includes a compound and that is for treating or preventing endothelial symptoms, disorders, or diseases, wherein, when the compound comes into contact with immortalized cells of Fuchs' corneal endothelial dystrophy, (i) said immortalized cells exhibit a cell survival rate (%) of approximately 90% or more after being cultured for 24-28 hours in Dulbecco's modified Eagle medium (DMEM) + 2% fetal bovine serum (FBS) + 1% penicillin/streptomycin (P/S), and (ii) the ratio of caspase 3/7 activity (%) in the presence of TGF-β with respect to said cellular survival rate (%) is at most 0.8 after being cultured for 24-28 hours in Dulbecco's modified Eagle medium (DMEM) + 2% fetal bovine serum (FBS) + 1% penicillin/streptomycin (P/S).
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 31/135 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone
A61K 31/138 - Aryloxyalkylamines, p. ex. propranolol, tamoxifène, phénoxybenzamine
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
A61K 31/665 - Composés du phosphore ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. fosfomycine
A61K 31/714 - Cobalamines, p. ex. cyanocobalamine, vitamine B12
A61P 3/02 - Nutriments, p. ex. vitamines, minéraux
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
93.
METHOD FOR PRODUCING ANTIMICROBIAL ZINC OXIDE POWDER
Provided is a method for producing a zinc oxide powder that exhibits an excellent antimicrobial performance even when blocked from light. This production method contains a step for adding 150-250 g of a hexagonal flake-shaped zinc oxide powder to 1 liter of an aqueous zinc nitrate solution having a concentration of 2-4 M (mol/L) and performing a hydrothermal treatment for 5-15 hours at 130°C-180°C, and a step for subjecting the basic zinc nitrate produced by this hydrothermal treatment to a heat treatment for 0.5-3 hours at a temperature of 550°C-700°C in air or an inert gas atmosphere. This heat treatment is preferably carried out at a temperature of 575°C-650°C, and the antimicrobial activity per unit mass can be increased by pulverizing the powder after the heat treatment.
Provided is an ion analyzer for generating product ions from specimen component-derived precursor ions, and analyzing such product ions, wherein the ion analyzer comprises: a reaction chamber (2) into which the precursor ions are introduced; a radical generation chamber (51); a source gas supply source (52) that introduces a source gas into the radical generation chamber (51); a vacuum exhaust unit (57) that exhausts the radical generation chamber (51); a vacuum discharge unit (53) that causes a vacuum discharge to be generated in the radical generation chamber (51); a radical irradiation unit (54) that irradiates inside the reaction chamber (2) the radicals generated from the source gas in the radical generation chamber (51); and a separation/detection unit (3) that separates and detects product ions generated from the precursor ions due to reaction with the radicals in accordance with the mass charge ratio and/or ion mobility.
G01N 27/62 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'ionisation des gaz, p. ex. des aérosolsRecherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant les décharges électriques, p. ex. l'émission cathodique
H01J 49/42 - Spectromètres à stabilité de trajectoire, p. ex. monopôles, quadripôles, multipôles, farvitrons
95.
RESIN COMPOSITION AND METHOD FOR DETERMINING FLAME RETARDANCY OF RESIN COMPOSITION
Provided are: a resin composition which is suitable for use in producing flame-retardant molded articles and which can impart high flame retardancy even when containing a flame retardant only in a small amount; and a flame retardancy determination method for determining the flame retardancy of a resin composition. The resin composition of the present invention comprises a thermoplastic resin, a cellulosic material, and a phosphoric-acid flame retardant and satisfies the following relationships (1) and (2). (In the relationships (1) and (2), TP, TB, and TCMP respectively indicate the following temperatures corresponding to peaks of weight loss rate in thermogravimetry: TP is the temperature (°C) at which the weight loss rate of the thermoplastic resin peaks, TB is the temperature (°C) at which the weight loss rate of the cellulosic material peaks, and TCMP is the temperature (°C) at which the weight loss rate of the resin composition peaks. In cases when the resin composition has two weight loss rate peaks, TCMP is the lower-temperature-peak temperature.)
C08L 1/00 - Compositions contenant de la cellulose, de la cellulose modifiée ou des dérivés de la cellulose
C08K 5/521 - Esters des acides phosphoriques, p. ex. de H3PO4
C08L 23/00 - Compositions contenant des homopolymères ou des copolymères d'hydrocarbures aliphatiques non saturés ne possédant qu'une seule liaison double carbone-carboneCompositions contenant des dérivés de tels polymères
C08L 67/04 - Polyesters dérivés des acides hydroxycarboxyliques, p. ex. lactones
C08L 101/00 - Compositions contenant des composés macromoléculaires non spécifiés
Provided are a coolant and a cooling device capable of reducing bad effects on human bodies. A cooling device 1A for cooling an engine mounted in a vehicle wherein a coolant is used for cooling an engine 2, said coolant containing no ethylene glycol and comprising, as a main component, a polyol ester which is a lubricating oil having a freezing point of -70°C or lower. The cooling device 1A, which comprises a coolant flow channel 3 for circulating the coolant and a pump 4 for allowing the coolant in the coolant flow channel 3 to flow, is characterized in that the pump 4 is a gear pump which allows the coolant to flow by gears.
F25D 9/00 - Dispositifs non associés à des machines frigorifiques et non couverts par les groupes Combinaisons de dispositifs compris dans plusieurs des groupes
H02K 9/19 - Dispositions de refroidissement ou de ventilation pour machines avec enveloppe fermée et circuit fermé de refroidissement utilisant un agent de refroidissement liquide, p. ex. de l'huile
C10N 20/00 - Propriétés physiques particulières des constituants des compositions lubrifiantes
C10N 20/06 - Particules de forme ou de dimensions particulières
C10N 30/00 - Propriétés physiques ou chimiques particulières améliorées par l'additif caractérisant la composition lubrifiante, p. ex. additifs multifonctionnels
C10N 40/04 - Bains d'huileBoîtes de vitessesTransmissions automatiquesMécanismes de traction
Provided is a transformer oil that has high environmental compatibility and is expected to be further improved in transformer cooling properties. A transformer oil prepared by mixing a vegetable oil with a silicone oil and contains no mineral oil, said transformer oil being characterized in that the ratio of the volume of the vegetable oil to the volume of the silicone oil is 3:7 to 7:3 and magnetic particles (e.g., temperature-sensitive magnetic particles) are dispersed in the transformer oil.
C10M 107/50 - Compositions lubrifiantes caractérisées en ce que le matériau de base est un composé macromoléculaire contenant du silicium
H01B 3/20 - Isolateurs ou corps isolants caractérisés par le matériau isolantEmploi de matériaux spécifiés pour leurs propriétés isolantes ou diélectriques composés principalement de substances organiques liquides, p. ex. huiles
H01B 3/46 - Isolateurs ou corps isolants caractérisés par le matériau isolantEmploi de matériaux spécifiés pour leurs propriétés isolantes ou diélectriques composés principalement de substances organiques matières plastiquesIsolateurs ou corps isolants caractérisés par le matériau isolantEmploi de matériaux spécifiés pour leurs propriétés isolantes ou diélectriques composés principalement de substances organiques résinesIsolateurs ou corps isolants caractérisés par le matériau isolantEmploi de matériaux spécifiés pour leurs propriétés isolantes ou diélectriques composés principalement de substances organiques cires silicones
C10N 30/00 - Propriétés physiques ou chimiques particulières améliorées par l'additif caractérisant la composition lubrifiante, p. ex. additifs multifonctionnels
C10N 40/16 - Usages électriques ou magnétiques diélectriquesHuiles isolantes
98.
MULTI-SCREW KNEADER AND METHOD FOR PRODUCING NANO-COMPOSITE USING SAID MULTI-SCREW KNEADER, AND DISK-SHAPED SEGMENT USED FOR SAID KNEADER AND SAID METHOD
Provided are: a multi-screw kneader in which extension and flow actions which act before and after small holes in a disk-shaped segment having the small holes can be sufficiently exhibited; a method for producing a nano-composite using the multi-screw kneader; and a disk-shaped segment used for said kneader and said method. This multi-screw kneader is provided with a plurality of kneading screws and a disk-shaped segment in a barrel. The disk-shaped segment partitions the inside of the barrel at a downstream side from a kneading material feeding part, and is provided with: a plurality of shaft penetrating sections through which the rotation shaft of each kneading screw pass in a rotatable manner; and a plurality of small holes which are perforated around the shaft penetrating sections and serve as flow passages for the kneading material. This method for producing a nano-composite includes a step of feeding nanoparticles as a resin additive by using the multi-screw kneader. This disk-shaped segment is provided with the shaft penetrating sections and the plurality of small holes.
B29B 7/48 - MélangeMalaxage continu, avec dispositifs mécaniques de mélange ou de malaxage avec dispositifs de mélange ou de malaxage mobiles rotatifs avec plus d'un arbre à dispositifs à engrènement, p. ex. à vis qui s'engrènent
99.
Liquid-crystal varifocal lens and focal length control method
A liquid-crystal varifocal lens includes a liquid crystal lens, and an ultrasonic transducer for generating an ultrasonic wave with a frequency that matches a resonant frequency of the liquid crystal lens. The ultrasonic transducer generates flexural oscillation in the liquid crystal lens such that the flexural oscillation has a vibration intensity decreasing continuously from the center to the circumference of a liquid crystal layer, whereby the thickness of the liquid crystal layer is changed, with the result that the orientation of the liquid crystal molecules is changed.
G02F 1/29 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p. ex. commutation, ouverture de porte ou modulationOptique non linéaire pour la commande de la position ou de la direction des rayons lumineux, c.-à-d. déflexion
G02F 1/11 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p. ex. commutation, ouverture de porte ou modulationOptique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur basés sur des éléments acousto-optiques, p. ex. en utilisant la diffraction variable par des ondes sonores ou des vibrations mécaniques analogues
B06B 1/06 - Procédés ou appareils pour produire des vibrations mécaniques de fréquence infrasonore, sonore ou ultrasonore utilisant l'énergie électrique fonctionnant par effet piézo-électrique ou par électrostriction
G02F 1/133 - Dispositions relatives à la structureExcitation de cellules à cristaux liquidesDispositions relatives aux circuits
G02F 1/1335 - Association structurelle de cellules avec des dispositifs optiques, p. ex. des polariseurs ou des réflecteurs
An ACAT inhibitor can be more efficiently delivered into the brain by means of a nasally administered medical composition containing: a monohydrochloride of 2-[4-[2-(benzimidazole-2-ylthio)ethyl]piperazine-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide; and an organic acid.
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
brevets
